ClinicalTrials.gg
RecruitingNCT07230847Updated Apr 6, 2026

A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography

An interventional study of BioFreedom™ and Xience in Coronary Heart Disease and Acute Coronary Syndrome, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.

Planned enrollment
11th of 13
60 · median 240
Started
2025
with 5 others
No phase
7 of 25
5 open now
Primary completion
2026-12
later than 6 of 12 live
Registered
20th of 25
by date

Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 20th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

BioFreedom™ is the world's first polymer-free drug-coated stent (DCS), utilizing a proprietary microstructured surface technology. Its abluminal microporous surface directly carries BA9™ (a sirolimus derivative) with high lipophilicity. This design mitigates inflammatory responses while promoting early vascular healing and reducing thrombotic risk. Extensive clinical evidence has validated BioFreedom™'s superior performance in high-bleeding-risk (HBR) populations. However, comprehensive assessments of neointimal coverage and quantitative neointimal transformation post-implantation remain insufficient. With advancements in ultra-high-resolution optical coherence tomography (OCT), detailed evaluation of coronary stent healing has become feasible. This study will employ OCT to comparatively assess vascular healing patterns-including neointimal transformation and strut coverage-in ACS patients with HBR receiving either the commercially available BioFreedom™ DCS or Xience drug-eluting stent system. The findings will provide multidimensional insights into the devices' post-implantation efficacy and safety profiles.

03

Conditions studied

  • Coronary Heart Disease
  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Male or non-pregnant female
  3. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI)
  4. No for coronary artery bypass grafting (CABG)
  5. High bleeding risk (HBR) patients per ARC-HBR definition (meeting ≥1 major or 2 minor criteria):

    Major Criteria:

    • Expected long-term oral anticoagulation
    • Severe/end-stage chronic kidney disease ( \<30 mL/min)
    • Moderate/severe anemia ( \<110 g/L)
    • Spontaneous bleeding requiring hospitalization/transfusion within 6 months (or recurrent)
    • Chronic bleeding diathesis
    • Moderate/severe thrombocytopenia pre-PCI ( count \<100×10⁹/L)
    • Liver cirrhosis with portal hypertension
    • Active in past 12 months (excluding non-melanoma skin cancer; defined as diagnosis/treatment within 12 months)
    • History of spontaneous intracranial hemorrhage
    • Traumatic intracranial hemorrhage within 12 months
    • Known cerebral arteriovenous malformation
    • Moderate/severe ischemic stroke within 6 months
    • Major surgery/severe trauma within 30 days pre-PCI
    • Planned non-deferrable major surgery during dual antiplatelet therapy

    Minor Criteria:

    • Age ≥75 years
    • Moderate chronic kidney disease (eGFR:30\~59 ml/min)
    • Mild anemia (male: Hb=110\~129 g/L; female: Hb=110\~119 g/L)
    • Spontaneous bleeding requiring hospitalization/transfusion within 6-12 months pre-PCI
    • Chronic NSAID/ use post-PCI
    • Ischemic stroke >6 months pre-PCI
  6. Capable of understanding trial objectives and providing

Angiographic Inclusion Criteria:

  1. Target lesion must be primary native coronary artery lesion
  2. Target lesion with ≥70% diameter stenosis (visual estimate), or 50-70% diameter stenosis (visual estimate) with ischemic evidence
  3. ≥1 non-target lesion requiring intervention
  4. Non-target lesions eligible for elective treatment within 1 month

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  1. Presence of ≥1 evidence of heart failure including:

    • Class III or higher, or
    • Killip classification ≥ Grade 2, or
    • (LVEF) ≤30% within 30 days pre-procedure (by echocardiography or intraoperative ventriculography)
  2. Cardiogenic shock patients
  3. Known allergies to: Aspirin / clopidogrel / ticagrelor / heparin, Contrast agents/drugs used in drug-eluting stents or to aspirin/ clopidogrel / ticagrelor
  4. \<12 months or factors potentially compromising clinical follow-up
  5. Participation in other drug/medical device trials prior to enrollment without reaching primary endpoint timelines
  6. History of substance abuse (alcohol/cocaine/heroin, etc.)
  7. Severe arrhythmias (e.g., high-risk ventricular premature contractions/ ventricular tachycardia)
  8. Other medical conditions deemed unsuitable by investigators

Angiographic Exclusion Criteria:

  1. Left main coronary artery disease
  2. Bypass graft lesions
  3. Evidence of extensive thrombus in target vessel
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    BioFreedom™ Drug-Coated Coronary Stent Intervention Group

    Device: BioFreedom™

  • Active comparator
    Xience Drug-Eluting Coronary Stent System Intervention Group

    Device: Xience

Interventions

  • DeviceBioFreedom™

    BioFreedom™ Drug-Coated Coronary Stent Intervention

  • DeviceXience

    Xience Drug-Eluting Coronary Stent System Intervention

06

What researchers measure

Primary outcomes

  1. OCT-Detected Neointimal Strut Coverage at 1-Month Post-Procedure

    Neointimal strut coverage was defined as: Covered strut proportion =Number of struts covered by neointima / Total number of analyzable struts A strut is considered covered when both its luminal surface and lateral sides demonstrate continuous neointimal tissue encapsulation.

    Time frame: 1-Month Post-Procedural Follow-Up

Secondary outcomes

  1. Neointimal thickness at 1-month post-procedure

    Strut neointimal thickness (NIT) will be analysed every 1 mm at 1-month post-procedure OCT follow-up

    Time frame: 1-Month Post-Procedural Follow-Up

  2. Neointimal area at 1-month post-procedure

    Lumen area and stent area will be analysed every 1 mm at 1-month post-procedure OCT follow-up, neointimal area (NIA) will be calculated as stent minus lumen area.

    Time frame: 1-Month Post-Procedure Follow-Up

  3. Neointimal volume at 1-month post-procedure

    Neointimal volume (NIV) and stent volume will be calculated using Simpson's rule and reported as total NIV, mean NIV (total NIV divided by length), and percent NIV (NIV divided by stent volume)

    Time frame: 1-Month Post-Procedure Follow-Up

  4. Incidence of Major Adverse Cardiac Events (MACE) within 12 Months Post-Procedure

    MACE is defined as a composite of cardiac death, myocardial infarction, and target vessel revascularization (TVR).

    Time frame: 12 Months Post-Procedure

  5. Incidence of stent thrombosis within 12 months post-procedure

    Stent thrombosis refers to definite or probable stent thrombosis as defined by the Academic Research Consortium (ARC) criteria

    Time frame: 12 Months Post-Procedure

  6. Incidence of bleeding events within 12 months post-procedure

    bleeding events including BARC types 2, 3, or 5 bleeding.

    Time frame: 12 Months Post-Procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Nov 17, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07230847
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Dec 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Yongjian Wu
Contact
fuwaiwyj@163.com
13701387189

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion